Latebreakers: FDA drug safety bill one step closer to reality

Article

Like the Senate, the House has passed a bill that would give the FDA more authority to ensure drug safety by requiring manufacturers to conduct postmarketing surveillance studies; demand more user fees; and other measures.

Like the Senate, the House has passed a bill that would give the FDA more authority to ensure drug safety by requiring manufacturers to conduct postmarketing surveillance studies; demand more user fees; and other measures. Since H.R. 2900 contains some provisions that are different from S. 1082, with the House version considered the stronger one, a conference committee will now have to come up with a new bill that both houses can approve before it is sent to the President for signature.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
© 2025 MJH Life Sciences

All rights reserved.